TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01325545

Intervention type: OTHER
Intervention: Mobile cardiac rhythm monitoring
Description: Continuous ambulatory cardiac rhythm monitoring using the CardioNet MCOT device

Intervention type: OTHER
Intervention: Mobile cardiac rhythm monitoring
Description: Continuous ambulatory cardiac rhythm monitoring using the CardioNet MCOT device
Study: NCT02340143

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Marketed partially hydrolyzed cow's milk protein infant formula

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Investigational
Description: Partially hydrolyzed cow's milk protein infant formula with a probiotic
Study: NCT05291130

Intervention type: DEVICE
Intervention: Plasmafit® Vitelene® Vitamin E
Description: Plasmafit® Acetabular Cup System with an insert Aesculap ® Vitelene ® Vitamin E Stabilized Highly Crosslinked Polyethylene and BIOLOX delta Ceramic Femoral Head or ISODUR® Metal Femoral Heads

Intervention type: DEVICE
Intervention: Plasmafit® Vitelene® Vitamin E
Description: Plasmafit® Acetabular Cup System with an insert Aesculap ® Vitelene ® Vitamin E Stabilized Highly Crosslinked Polyethylene and BIOLOX delta Ceramic Femoral Head or ISODUR® Metal Femoral Heads
Study: NCT03113110

Intervention type: DRUG
Group type: OTHER
Intervention: Empagliflozin 10 mg
Description: PTDM patients on previous antidiabetic treatment (\<40 IU insulin (in some cases plus oral antidiabetics)) receive Empagliflozin, ideally as monotherapy
Study: NCT04273516

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 2.5 Mg Oral Tablet
Description: Tablet Rivaroxaban 2.5 mg 2 times daily add to standard treatment ASA 80 mg daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rivaroxaban placebo tablets
Description: Placebo tablets add to ASA 80 mg daily that is standard treatment
Study: NCT04506723

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous Nephrolithotomy
Description: PCNL will be carried out in accordance with the standards and capabilities of the medical center. After the procedure pathomorphological data of the renal parenchyma will be assessed

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Partial nephrectomy
Description: Partial nephrectomy will be carried out in accordance with the standards and capabilities of the medical center. After the procedure pathomorphological data of the renal parenchyma will be assessed

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radical nephrectomy
Description: Nephrectomy will be carried out in accordance with the standards and capabilities of the medical center. After the procedure pathomorphological data of the renal parenchyma will be assessed
Study: NCT03518086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirikizumab
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirikizumab
Description: Administered IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered IV
Study: NCT02258594

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Web-Based Patient Centered Toolkit (PCTK)
Description: The PCTK provides patients/care partners tailored health information regarding conditions, test results, and medications presented at a consumer health literacy level, and the ability to communicate with care team members via patient-facing tools accessible from bedside tablet computers. The PCTK allows patients to post questions to their care team members via a patient-centered microblog. The microblog facilitates development of a collaborative patient plan of care. The provider-facing PCTK includes tools that engage care team members in 1) completing a safety checklist and viewing a safety dashboard; 2) viewing patient-inputted information (goals, preferences, concerns) regarding the plan of care; 3) identifying clinical problems, care team goals, and patient schedules for education and multidisciplinary communication; 4) messaging patients on the patient thread; and 5) discussing patient's plan of care with other providers via the provider thread.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Patient-SatisfActive® Model
Description: The Patient-SatisfActive Model is a structured, pro-active, patient-centered care model that aims at improving patient satisfaction by enhancing the degree to which patients' needs, concerns and expectations are met and by preserving dignity and respect. The model comprises steps that enhance interpersonal communication between clinicians and patients, incorporates clinicians' efforts to ascertain, address and document patients' needs, concerns, expectations and perceptions throughout hospitalization, and includes elements that empower and engage patients in their care.
Study: NCT01878318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: stable dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab [RoActemra/Actemra]
Description: 8 mg/kg intravenously every 4 weeks, 24 weeks
Study: NCT03827694

Intervention type: DIAGNOSTIC_TEST
Intervention: Non-Invasive Testing for PIFI
Description: galactomannan assay, fungal PCRs, cell-free next-generation DNA/RNA sequencing, RNAseq
Study: NCT03758599

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Climbing
Description: All interventions are identical in their duration. To fulfill the WHO guidelines of health enhancing activity (minimum 150 minutes of moderate exercise per week), two 75 minutes exercise sessions per week will take place. After meeting the inclusion criteria and after allocation to one of the three groups, patients will receive their timetable with the exercise or group session dates.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nordic Walking
Description: All interventions are identical in their duration. To fulfill the WHO guidelines of health enhancing activity (minimum 150 minutes of moderate exercise per week), two 75 minutes exercise sessions per week will take place. After meeting the inclusion criteria and after allocation to one of the three groups, patients will receive their timetable with the exercise or group session dates.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Social Contact
Description: All interventions are identical in their duration. To fulfill the WHO guidelines of health enhancing activity (minimum 150 minutes of moderate exercise per week), two 75 minutes exercise sessions per week will take place. After meeting the inclusion criteria and after allocation to one of the three groups, patients will receive their timetable with the exercise or group session dates.
Study: NCT03932461

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vacuum assisted closure
Description: The Vacuum assisted closure system consists of an abdominal dressing covering the intra abdominal viscera over the dressing there will be placed a blue sponge which will be covered by drape and connected to a vacuum pump.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Relaparotomy on demand
Description: Abdomen is closed at the index operation after source of peritonitis is treated. Every 48-hours the patients are evaluated for the need of relaparotomy based on clinical and paraclinical parameters.
Study: NCT06611904

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dulaglutide
Description: Combined treatment with dulaglutide and dapagliflozin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DPP-4 Inhibitors
Description: DPP-4i treatment as an add-on to metformin
Study: NCT01989013

Intervention type: OTHER
Group type: OTHER
Intervention: biweekly intervention
Description: 10 step craniosacral therapy protocol through manual therapy at feet , thoracic diaphragm, neck and cranium
Study: NCT03414242

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cervical spine musculature
Description: Previously established cervical spine musculature training methodology will be utilized to develop a concussion prevention training program.
Study: NCT02155452

Intervention type: PROCEDURE
Intervention: ALA
Description: Prior to surgery all patients would receive freshly prepared solution of 5-ALA, 20 mg/kg bodyweight dissolved in 100 ml of potable water orally approximately 4 hours (range 4-6 hrs) before the commencement of anesthesia induction for surgery.~The surgery would then be performed with the help of navigation. After craniotomy, the navigation software would be used to identify the selected target areas based on the preoperative images (MR as well as PET when available) and directed image-guided biopsies from these representative areas will be collected for histological evaluation
Study: NCT04784507

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: En Bloc Resection
Description: En bloc transurethral resection of bladder tumor (EBR-BT) using any energy source (laser and bipolar or monopolar energy)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Transurethral Resection Bladder Tumor (Mono/Bipolar)
Description: Conventional Transurethral Resection Bladder Tumor (Mono/Bipolar)
Study: NCT03416192

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MCO-HD
Description: Measurements will be done after 0,4,8 and 12 weeks of hemodialysis with Medium Cut-Off filter.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MCO-HD
Description: Measurements will be done after 0,4,8 and 12 weeks of hemodialysis with Medium Cut-Off filter.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: high-flux HDF
Description: Measurements will be done after 0,4,8 and 12 weeks of hemodiafiltration with standard high-flux filter

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high-flux HDF
Description: Measurements will be done after 0,4,8 and 12 weeks of hemodiafiltration with standard high-flux filter
Study: NCT01461733

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amiodarone
Description: standard dose amiodarone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo delivered blinded
Study: NCT00570960

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextran 70
Description: dextran 70, 1.0 g/kg on days one, two and three

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: human albumin
Description: human albumin 1.5 g/kg on day one and 1.0 g/kg on day three
Study: NCT04367662

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: blood sampling
Description: blood sampling in hospitalized patient for COVID-19 infection
Study: NCT03020628

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NBP607-QIV
Description: For subjects 6 months to 35 months of age, Single dose administration, Intra-muscular \[\* 2 doses for subjects without influenza vaccination history, administered at least 4 weeks apart\]

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: NBP607-TIV
Description: For subjects 6 months to 35 months of age, Single dose administration, Intra-muscular \[\* 2 doses for subjects without influenza vaccination history, administered at least 4 weeks apart\]
Study: NCT04017715

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: warm up
Description: Phase 1 is dynamic stretching and running exercises which includes, A jogging ,B walking lunge and sweeps, C hip in and out running : jog 3 steps stop and do hip in/hip out for Phase 2 is strength and agility which includes A- squat, B- push-ups: wide palmer push-ups. C vertical jumps. D- lateral jump. E- nordic hamstrings,. F (a)- shoulder external rotations, F(b)- modified inverted rows, Phase 3 is balance and core strength which includes A- modified ankle discs, B - planks: standard forward planks 2 repetitions for 30secs. C- side planks: standard side planks on both sides 1 repetition for 20 secs. Da- bird-dog,Db- modified back extensions, Phase 4 is run sprint which includes A- run sprint: 100% speed running between running (20m) with 1 repetition

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: cool down
Description: Phase 1 is dynamic stretching and running exercises which includes, A jogging ,B walking lunge and sweeps, C hip in and out running : jog 3 steps stop and do hip in/hip out for Phase 2 is strength and agility which includes A- squat, B- push-ups: wide palmer push-ups. C vertical jumps. D- lateral jump. E- nordic hamstrings,. F (a)- shoulder external rotations, F(b)- modified inverted rows, Phase 3 is balance and core strength which includes A- modified ankle discs, B - planks: standard forward planks 2 repetitions for 30secs. C- side planks: standard side planks on both sides 1 repetition for 20 secs. Da- bird-dog,Db- modified back extensions, Phase 4 is run sprint which includes A- run sprint: 100% speed running between running (20m) with 1 repetition

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No intervention: control
Description: sprint exercise and general stretching as conventional protocol as follows in star club
Study: NCT04959409

Intervention type: DRUG
Intervention: Topical analgesia (EMLA or AMETOP)
Description: Whether topical analgesia has or has not been administered to each child prior to them receiving an inhalational induction of anaesthesia
Study: NCT03191565

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Paper diary sheet
Description: Writing skill-use and symptoms on a week matrix type sheet

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Monsenso DBT-app and IT monitoring program
Description: Entering skill-use and symptoms on a smartphone with Monsenso DBT-app and IT monitoring program
Study: NCT01559610

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Intervention Group
Description: The patients were instructed by a nurse

Intervention type: OTHER
Group type: OTHER
Intervention: Intervention Group
Description: The patients were instructed by a nurse
Study: NCT00734708

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trafermin (genetical recombination)
Description: Administered to the bone defect during flap operation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Control
Study: NCT03963219

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ABC4D
Description: The complete integrated system consists of a smartphone that holds the advanced decision support algorithm. The system requires regular updates of cases derived from continuous glucose monitoring (CGM) data. Each new case includes information about the problem (e.g. capillary blood glucose, meal information and physical exercise), solution (recommended insulin dose) and outcome (post-prandial blood glucose).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Bolus Calculator
Description: Standard bolus calculator
Study: NCT00329693

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Norprolac
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norprolac
Description: Quinagolide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norprolac
Description: Quinagolide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norprolac
Description: Quinagolide
Study: NCT02437994

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pulmonary Rehabilitation
Description: The rehabilitation program will be multidisciplinary and will include mandatory supervised exercise training at appropriate training intensity, other components of the program can be breathing control and relaxation techniques, methods of clearance of pulmonary secretions, disease education, dietary advice, and psychological support on issues relating to chronic disability. Six minute walking tests, and improvements in dyspnea sensation (CRDQ) will be used to benchmark the effect of a program provided by a given team.
Study: NCT01984957

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Muscle biopsy
Description: open muscular biopsy of the deltoid under local anaesthesia
Study: NCT00410072

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: Tablets, Oral, ETV = 0.5 mg, once daily, 100 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir + Tenofovir
Description: Tablets, Oral, ETV = 0.5 mg + TFV = 300 mg, once daily, 100 weeks
Study: NCT03576443

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idelalisib
Description: Idelalisib 150 mg x 2 p o
Study: NCT01470703

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ECMO (Quadrox®, Jostra®, Maquet®)
Description: ECMO will be initiated as rapidly as possible by venovenous access. The material to be used consists of pre-heparinized cannulae and tubing, a centrifuge pump (CardioHelp®) and a heparinized membrane oxygenator (Quadrox®, Jostra®, Maquet®). To minimize the trauma induced by mechanical ventilation, the following ventilator settings will be used: volume-assist control mode, FiO2 30-60%, PEEP ≥10 cm H2O, VT lowered to obtain a plateau pressure \<25 cm H2O, respiration rate (RR) 10-30/minute or APRV mode with high pressure level \<25 cm H2O and low pressure level ≥10 cm H2O

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional care
Description: Standard management of ARDS, according to the modalities applied by the 'maximal pulmonary recruitment' group in the EXPRESS trial (1): assist-controlled ventilatory mode, VT set at 6 ml/kg of ideal body weight and PEEP set so as not to exceed a plateau pressure of 28-30 cm H2O. In the case of refractory hypoxemia, the usual adjunctive therapeutics can be used: NO, prone position, HFO ventilation, almitrine infusion. A cross-over option to ECMO will be possible in the case of refractory hypoxemia defined as blood arterial saturation SaO2 \<80% for \>6 hours, despite mandatory use of recruitment maneuvers, and inhaled NO/prostacyclin and if technically possible a test of prone position, and only if the patient has no irreversible multiple organ failure and if the physician in charge of the patient believes that this could actually change the outcome
Study: NCT04090385

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Direct Current Stimulation
Description: Participants will receive 15 sessions of Transcranial Direct Current Stimulation (tDCS) for 20 minutes each at 2 mA intensity, 5 times a week. The current will be delivered via saline-embedded sponge surface electrodes using a battery-powered neurostimulator (TCT-Research, Trans Cranial Technologies, Hong Kong). A small active specific electrode (5x5 cm) will be used to prevent coverage of adjacent areas, resulting in a current density of 0.08 mA / cm². These parameters are within the safe limits established in previous human studies.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation
Description: Participants will receive 15 sessions of Transcranial Direct Current Stimulation (tDCS) for 20 minutes each at 2 mA intensity, 5 times a week. The current will be delivered via saline-embedded sponge surface electrodes using a battery-powered neurostimulator (TCT-Research, Trans Cranial Technologies, Hong Kong). A small active specific electrode (5x5 cm) will be used to prevent coverage of adjacent areas, resulting in a current density of 0.08 mA / cm². These parameters are within the safe limits established in previous human studies.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation
Description: Participants will receive 15 sessions of Transcranial Direct Current Stimulation (tDCS) for 20 minutes each at 2 mA intensity, 5 times a week. The current will be delivered via saline-embedded sponge surface electrodes using a battery-powered neurostimulator (TCT-Research, Trans Cranial Technologies, Hong Kong). A small active specific electrode (5x5 cm) will be used to prevent coverage of adjacent areas, resulting in a current density of 0.08 mA / cm². These parameters are within the safe limits established in previous human studies.
Study: NCT03493438

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: A hot pack and conventional transcutaneous electrical stimulation (TENS) will be applied with a Chattanoga Intelect® stimulator for 20 minutes at a frequency of 100 Hz and a transition time of 60 μs. The duration of application was 3 days per week and six weeks for each of the four groups. These practices were also applied to individuals in all four groups.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: A hot pack and conventional transcutaneous electrical stimulation (TENS) will be applied with a Chattanoga Intelect® stimulator for 20 minutes at a frequency of 100 Hz and a transition time of 60 μs. The duration of application was 3 days per week and six weeks for each of the four groups. These practices were also applied to individuals in all four groups.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: A hot pack and conventional transcutaneous electrical stimulation (TENS) will be applied with a Chattanoga Intelect® stimulator for 20 minutes at a frequency of 100 Hz and a transition time of 60 μs. The duration of application was 3 days per week and six weeks for each of the four groups. These practices were also applied to individuals in all four groups.

Intervention type: OTHER
Group type: OTHER
Intervention: exercise
Description: A hot pack and conventional transcutaneous electrical stimulation (TENS) will be applied with a Chattanoga Intelect® stimulator for 20 minutes at a frequency of 100 Hz and a transition time of 60 μs. The duration of application was 3 days per week and six weeks for each of the four groups. These practices were also applied to individuals in all four groups.
Study: NCT02627573

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Unrelated allogeneic stem cell transplantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Unrelated allogeneic stem cell transplantation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine monophosphate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine monophosphate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymoglobulin
Study: NCT01290952

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Off-pump bypass surgery
Description: is a method of performing a coronary bypass operation for the purpose of treating advanced coronary heart disease while the heart is still beating normally.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: On-pump bypass surgery
Description: is a technique that temporarily takes over the function of the heart and lungs during surgery, maintaining the circulation of blood and the oxygen content of the body.